• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Primary Resistance to Alectinib Was Lost after Bevacizumab Combined Chemotherapy in ALK-Rearranged Lung Adenocarcinoma.

作者信息

Nakasuka Takamasa, Ichihara Eiki, Makimoto Go, Maeda Yoshinobu, Kiura Katsuyuki

机构信息

Department of Allergy and Respiratory Medicine, Okayama University Hospital, Okayama, Japan.

Department of Allergy and Respiratory Medicine, Okayama University Hospital, Okayama, Japan.

出版信息

J Thorac Oncol. 2019 Aug;14(8):e168-e169. doi: 10.1016/j.jtho.2019.03.009.

DOI:10.1016/j.jtho.2019.03.009
PMID:31345339
Abstract
摘要

相似文献

1
Primary Resistance to Alectinib Was Lost after Bevacizumab Combined Chemotherapy in ALK-Rearranged Lung Adenocarcinoma.在贝伐单抗联合化疗后，ALK重排肺腺癌对阿来替尼的原发性耐药消失。
J Thorac Oncol. 2019 Aug;14(8):e168-e169. doi: 10.1016/j.jtho.2019.03.009.
2
Alectinib treatment response in lung adenocarcinoma patient with novel EML4-ALK variant.新型 EML4-ALK 变异肺腺癌患者的艾乐替尼治疗反应。
Thorac Cancer. 2018 Oct;9(10):1327-1332. doi: 10.1111/1759-7714.12834. Epub 2018 Aug 21.
3
Activity of Brigatinib in the Setting of Alectinib Resistance Mediated by ALK I1171S in ALK-Rearranged Lung Cancer.布加替尼在ALK重排肺癌中由ALK I1171S介导的阿来替尼耐药情况下的活性。
J Thorac Oncol. 2019 Jan;14(1):e1-e3. doi: 10.1016/j.jtho.2018.06.020. Epub 2018 Jul 5.
4
VIT-ALK, a Novel Alectinib-Sensitive Fusion Gene in Lung Adenocarcinoma.VIT-ALK，一种在肺腺癌中发现的新型对阿来替尼敏感的融合基因。
J Thorac Oncol. 2018 May;13(5):e72-e74. doi: 10.1016/j.jtho.2017.11.134.
5
Safety and Efficacy of Alectinib in a Patient With Advanced NSCLC Undergoing Hemodialysis.阿来替尼在一名接受血液透析的晚期非小细胞肺癌患者中的安全性和有效性
J Thorac Oncol. 2019 Mar;14(3):e50-e52. doi: 10.1016/j.jtho.2018.11.012.
6
Alectinib Resistance in ALK-Rearranged Lung Cancer by Dual Salvage Signaling in a Clinically Paired Resistance Model.ALK 重排肺癌中双重挽救信号导致的阿来替尼耐药：在临床配对耐药模型中的研究。
Mol Cancer Res. 2019 Jan;17(1):212-224. doi: 10.1158/1541-7786.MCR-18-0325. Epub 2018 Aug 31.
7
Transformation of ALK rearrangement-positive adenocarcinoma to small-cell lung cancer in association with acquired resistance to alectinib.ALK重排阳性腺癌转化为小细胞肺癌并伴有对阿来替尼获得性耐药。
Ann Oncol. 2016 May;27(5):953-5. doi: 10.1093/annonc/mdw032. Epub 2016 Jan 24.
8
Case Report of Non-Small Cell Lung Cancer with STRN-ALK Translocation: A Nonresponder to Alectinib.伴有STRN-ALK易位的非小细胞肺癌病例报告：对阿来替尼无反应者
J Thorac Oncol. 2017 Dec;12(12):e202-e204. doi: 10.1016/j.jtho.2017.08.009.
9
Apatinib reverses alectinib resistance by targeting vascular endothelial growth factor receptor 2 and attenuating the oncogenic signaling pathway in echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion gene-positive lung cancer cell lines.阿帕替尼通过靶向血管内皮生长因子受体 2 和抑制棘皮动物微管相关蛋白样 4-间变性淋巴瘤激酶融合基因阳性肺癌细胞系中的致癌信号通路逆转艾乐替尼耐药。
Anticancer Drugs. 2018 Nov;29(10):935-943. doi: 10.1097/CAD.0000000000000667.
10
Alectinib is effective, safe and tolerable in an adolescent with stage IVB ALK-rearranged adenocarcinoma of the lung.阿来替尼对一名患有IVB期ALK重排肺腺癌的青少年患者有效、安全且耐受性良好。
Pediatr Hematol Oncol. 2018 Oct-Nov;35(7-8):415-421. doi: 10.1080/08880018.2018.1541492. Epub 2018 Dec 9.

引用本文的文献

1
Mechanisms of Resistance to ALK Inhibitors and Corresponding Treatment Strategies in Lung Cancer.肺癌中对ALK抑制剂的耐药机制及相应治疗策略
Int J Gen Med. 2025 Apr 15;18:2151-2171. doi: 10.2147/IJGM.S512395. eCollection 2025.
2
Anaplastic lymphoma kinase inhibitors-a review of anticancer properties, clinical efficacy, and resistance mechanisms.间变性淋巴瘤激酶抑制剂——抗癌特性、临床疗效及耐药机制综述
Front Pharmacol. 2023 Oct 25;14:1285374. doi: 10.3389/fphar.2023.1285374. eCollection 2023.
3
Systematic Analysis and Identification of Molecular Subtypes of TRP-Related Genes and Prognosis Prediction in Lung Adenocarcinoma.
肺腺癌中TRP相关基因分子亚型的系统分析、鉴定及预后预测
J Oncol. 2022 Aug 31;2022:5388283. doi: 10.1155/2022/5388283. eCollection 2022.
4
Anti-Angiogenic Therapy in Rearranged Non-Small Cell Lung Cancer (NSCLC).抗血管生成治疗在非小细胞肺癌（NSCLC）中的应用。
Int J Mol Sci. 2022 Aug 9;23(16):8863. doi: 10.3390/ijms23168863.
5
Anaplastic lymphoma kinase-special immunity and immunotherapy.间变性淋巴瘤激酶-特异性免疫与免疫治疗。
Front Immunol. 2022 Jul 25;13:908894. doi: 10.3389/fimmu.2022.908894. eCollection 2022.
6
Efficacy and safety of crizotinib plus bevacizumab in positive non-small cell lung cancer: an open-label, single-arm, prospective observational study.克唑替尼联合贝伐单抗治疗ALK阳性非小细胞肺癌的疗效与安全性：一项开放标签、单臂、前瞻性观察性研究。
Am J Transl Res. 2021 Mar 15;13(3):1526-1534. eCollection 2021.
7
Lorlatinib and Bevacizumab Activity in Rearranged Lung Cancers After Lorlatinib Progression.劳拉替尼进展后，劳拉替尼与贝伐单抗在重排型肺癌中的活性。
JCO Precis Oncol. 2020 Nov 2;4. doi: 10.1200/PO.20.00271. eCollection 2020.
8
Identification of prognostic markers of lung cancer through bioinformatics analysis and in vitro experiments.通过生物信息学分析和体外实验鉴定肺癌的预后标志物。
Int J Oncol. 2020 Jan;56(1):193-205. doi: 10.3892/ijo.2019.4926. Epub 2019 Nov 28.